Clinical trials: Advanced Age
Age-Related Macular Degeneration
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD
The purpose of his study is to evaluate the long term safety and tolerability of MA09-hRPE cellular therapy in patients with advanced dry Age-Related Macular Degeneration (AMD) from one to five years following the surgical…
- Trial name
- NCT02463344
- Testing
- MA09-hRPE
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Atrial Fibrillation
Pulmonary Vein Ablation Versus Amiodarone in the Elderly
The purpose of the study is to demonstrate that in patients of 70 years or older with symptomatic paroxysmal atrial fibrillation (AF) pulmonary vein isolation (PVI) using RF ablation therapy is superior to medical treatment with…
- Trial name
- PAVANE (NCT01276093)
- Testing
- PVI ablation, Amiodarone
- Where
- 6 sites in Netherlands
- Volunteers
- 59 people
- Sponsor
- Abbott Medical Devices
Healthy, Non-Smoking
Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects
1. Characterize the tolerability and safety of repeated doses of varenicline in healthy non-smoking elderly subjects. 2. Describe the steady state pharmacokinetics of varenicline in healthy non-smoking elderly subjects. 3.
- Trial name
- NCT00694044
- Testing
- varenicline
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer's Disease
A Safety and Tolerability Study of ABT-126 in Elderly
The objectives of this study are to assess the safety, tolerability and pharmacokinetics of ABT-126 in elderly subjects.
- Trial name
- NCT00867399
- Testing
- ABT-126
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Abbott
Age-Related Macular Degeneration
Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration
Palomid 529 is a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway having broad activity in angiogenesis and cellular proliferation.
- Trial name
- P52901 (NCT01033721)
- Testing
- Palomid 529
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Paloma Pharmaceuticals, Inc.
Healthy Volunteers
Safety, Tolerability, and Pharmacokinetics Study of ATH-1020
This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of ATH-1020 in healthy young and elderly subjects.
- Trial name
- NCT05169671
- Testing
- ATH-1020
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- LeonaBio
Dry Age Related Macular Degeneration
Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration
This is a safety and tolerability trial to evaluate the effect of subretinal injection of human embryonic stem cell derived retinal pigment epithelium cells in patients with dry Age Related Macular Degeneration (AMD) and to…
- Trial name
- Dry AMD (NCT01344993)
- Testing
- MA09-hRPE
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Healthy
Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly and and Healthy Younger Adult Participants
The purpose of this study is to compare the pharmacokinetics, safety, and tolerability of intranasally administered esketamine in elderly participants (greater than equal to [>=] 75 years of age) and younger healthy adult…
- Trial name
- NCT02345148
- Testing
- Esketamine
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteers
Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants
The study will consist of 2 parts, Study Parts 1 (1a: single ascending dose [SAD] Phase; and 1b: Food Effect Phase) and Part 2 (multiple ascending dose [MAD] Phase).
- Trial name
- NCT07613684
- Testing
- MF-300 SAD, MF-300 Food Effect, MF-300 MAD
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Epirium Bio Inc.
Risk Behavior, Cognitive Decline
Efficacy of a Multidomain Intervention on Lifestyle Risk Factors for Dementia Prevention
Alzheimer's Disease (AD) and other Dementias have far-reaching consequences on the lives of sufferers and their loved ones, not to mention the impact on the healthcare system.
- Trial name
- NCT06748625
- Testing
- Luci Coach-Assisted Intervention
- Where
- Canada
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- LuciLab
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older
The purpose of this study is to evaluate the immunogenicity, reactogenicity and safety of Fluviral™ containing the influenza strains recommended for the 2013-2014 season in adults aged 18 years and older.
- Trial name
- NCT01878825
- Testing
- Fluviral™
- Where
- Canada
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
XEROSTOMIA
OGT Spray in the Management of Xerostomia in the Elderly
The primary objective of the trial is to evaluate the efficacy, safety and clinical acceptability of OGT oromucosal spray in the relief of symptoms and signs of xerostomia in comparison with a saliva substitute (European Medical…
- Trial name
- NCT00350350
- Testing
- oxygenated oil, medical device. Spray containing essentially oxygenated oil
- Where
- France
- Volunteers
- 74 people
- Sponsor
- Laboratoires CARILENE
Cognitive Decline, Mild Cognitive Impairment
The Effects of Chicken Extract and a Peptide Supplement for the Prevention of Cognitive Decline in Non-demented Elderly Adults
This trial investigates the effect of a chicken extract supplement and a peptide supplement on cognitive function and potential mechanisms of action of cognitive decline during ageing, among non-demented elderly adults using a…
- Conditions
- Cognitive Decline, Mild Cognitive Impairment, Aging
- Trial name
- NCT04555655
- Testing
- Chicken extract supplement, Peptide Supplement
- Where
- 3 sites in Taiwan
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Brand's Suntory Asia
Lymphocytic Leukemia, Chronic
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
This single arm, open-label study will assess the safety and efficacy of low dose fludarabine and cyclophosphamide in combination with standard dose MabThera/Rituxan (rituximab) as primary therapy in elderly patients (>/= 65…
- Trial name
- NCT01263704
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 12 sites in Israel
- Volunteers
- 42 people
- Sponsor
- Hoffmann-La Roche
Parkinson Disease
Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease
The purpose of this study is to describe the safety and efficacy of opicapone plus standard of care in elderly patients with PD in the real-world setting
- Trial name
- NCT03959540
- Testing
- Opicapone, Levodopa (L-DOPA) + Standard care
- Where
- United Kingdom
- Volunteers
- 39 people
- Sponsor
- Bial - Portela C S.A.
Acute Lymphoblastic Leukemia
Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia
The main purpose of this study is to determine the maximum tolerated and efficient dose of GRASPA® in combination with polychemotherapy treatment of elderly patients with ALL, 55 years and over, Philadelphia chromosome-negative…
- Trial name
- NCT01523782
- Testing
- GRASPA
- Volunteers
- 30 people
- Sponsor
- ERYtech Pharma
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data
The objective of this study is to investigate safety and effectiveness of apixaban compared to warfarin in very elderly patients with Non-valvular atrial fibrillation (NVAF).
- Trial name
- NCT05438888
- Testing
- Warfarin, Apixaban
- Where
- Japan
- Volunteers
- 77,814 people
- Sponsor
- Pfizer
Influenza
Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly
The purpose of the study is to evaluate safety, tolerability and immunogenicity (in a subset) following a dose of a trivalent subunit influenza vaccine produced either in mammalian cells or in embryonated hen eggs, in healthy…
- Trial name
- NCT00306527
- Testing
- Cell culture derived influenza vaccine, egg-derived influenza subunit vaccine
- Where
- 5 sites in Poland
- Volunteers
- 2,235 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Healthy Subjects
Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects
This study had an open-label, single-dose design. All subjects received a single dose of 30 mg of intranasal ketorolac. Blood samples for determination of ketorolac plasma levels were obtained pre-dose and at specified time…
- Trial name
- NCT01365624
- Testing
- Ketorolac tromethamine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- American Regent, Inc.
Healthy Adults
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
We are doing this research to learn how healthy younger and older adults use two forms of vitamin B3-called nicotinamide mononucleotide (NMN) and nicotinamide (NAM)-to make NAD+.
- Trial name
- NCT06882096
- Testing
- Nicotinamide Mononucleotide (NMN), Nicotinamide (NAM)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Metro International Biotech, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.